Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis

Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis

Background and AimsThe clinical benefit of adjuvant antiviral therapy after curative therapy for HCC in patients with high preoperative HBV-DNA loads has been studied widely but that in patients with low preoperative HBV-DNA loads remains controversial. The purpose of this study was to determine the...

Full description

Bibliographic Details
Main Authors:	Kai-Xuan Liu, Jian-Guo Hong, Rui Wu, Zhao-Ru Dong, Ya-Fei Yang, Yu-Chuan Yan, Chun-Cheng Yang, Lun-Jie Yan, Sheng-Yu Yao, Hai-Chao Li, Xu-Ting Zhi, Tao Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-02-01
Series:	Frontiers in Oncology
Subjects:	hepatocellular carcinoma HBV reactivation antiviral therapy prognosis HBV-DNA load
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.605648/full

Similar Items

Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma
by: Jian Liu, et al.
Published: (2023-02-01)

On-treatment risks of cirrhosis and hepatocellular carcinoma among a large cohort of predominantly non-Asian patients with non-cirrhotic chronic hepatitis B
by: Zeyuan Yang, et al.
Published: (2023-10-01)

Comprehensive investigation of HBV-related hepatocellular carcinoma and choice of anti-HBV therapy
by: Huihui Lu, et al.
Published: (2021-08-01)

HBV mutations in EnhII/BCP/PC region contribute to the prognosis of hepatocellular carcinoma
by: Zijun Ge, et al.
Published: (2019-06-01)

HBx and YAP expression could promote tumor development and progression in HBV-related hepatocellular carcinoma
by: Chiyumi Oda, et al.
Published: (2022-12-01)

The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation
by: Sara Battistella, et al.
Published: (2023-04-01)

Extrahepatic Manifestations of Chronic HBV Infection and the Role of Antiviral Therapy
by: Cesare Mazzaro, et al.
Published: (2022-10-01)

Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes
by: Francisco Campello do Amaral Mello, et al.
Published: (2012-05-01)

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
by: Jin Zhang, et al.
Published: (2023-03-01)

Primary hepatocellular carcinoma in HBV infected patient - a case report
by: Patrycja Łanowy, et al.
Published: (2019-09-01)

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections
by: Erik De Clercq, et al.
Published: (2010-05-01)

Screening and validation of prognostic indicator genes in the progression of HBV related hepatocellular carcinoma
by: Jinglin Wang, et al.
Published: (2023-03-01)

Metabolomic Profiles for HBV Related Hepatocellular Carcinoma Including Alpha-Fetoproteins Positive and Negative Subtypes
by: Jianping Sun, et al.
Published: (2019-10-01)

Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection
by: Jian-Lin Chen, et al.
Published: (2016-03-01)

Editorial: HBV and lymphoma
by: Giuseppe Gentile, et al.
Published: (2023-07-01)

HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors
by: Jiaming Shen, et al.
Published: (2023-05-01)

HBV and HDV: New Treatments on the Horizon
by: Valentina Zuccaro, et al.
Published: (2021-09-01)

Using the Quantitative Determination of HbsAg to Monitor Antiviral Therapy of Chronic HBV-Infection
by: I.A. Zaitsev
Published: (2015-04-01)

HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review
by: Giuseppe Gentile, et al.
Published: (2019-11-01)

Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161
by: Angela M. Lam, et al.
Published: (2024-02-01)

Evaluation of the effect of three disinfectants on removing HBV contamination
by: Arami S, et al.
Published: (2006-06-01)

Persistent Hepatitis B Viraemia with Polymerase Mutations among HIV/HBV Co-Infected Patients on HBV-Active ART in KwaZulu-Natal, South Africa
by: Nokukhanya Msomi, et al.
Published: (2022-04-01)

Single-cell landscape of immune cells during the progression from HBV infection to HBV cirrhosis and HBV-associated hepatocellular carcinoma
by: Qingquan Bai, et al.
Published: (2023-12-01)

Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment
by: Zhang Dake, et al.
Published: (2012-12-01)

In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma
by: Ye Zheng, et al.
Published: (2022-01-01)

Exploring the Therapeutic Potentials of iNKT Cells for Anti-HBV Treatment
by: Agnieszka Lawrenczyk, et al.
Published: (2014-07-01)

HBV genotypes circulation in pregnant women in Romania: a pilot study
by: Popovici Odette, et al.
Published: (2020-01-01)

HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure
by: Maryam Moini, et al.
Published: (2022-03-01)

Treatment of patients with HBV cirrhosis: Successes, unsolved problems
by: I G Bakulin, et al.
Published: (2013-12-01)

HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation
by: Lorenzo Piermatteo, et al.
Published: (2021-09-01)

Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients
by: Carlotta Cerva, et al.
Published: (2022-02-01)

Risk stratification of HBV infection in Asia-Pacific region
by: Jia-Horng Kao
Published: (2014-09-01)

Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure
by: Romina Salpini, et al.
Published: (2022-09-01)

High-sensitivity HBV DNA test for the diagnosis of occult HBV infection: commonly used but not reliable
by: Chengwei Wang, et al.
Published: (2023-05-01)

Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis
by: Ping Li, et al.
Published: (2021-07-01)

Concept of HBV and HCV as a risk factor and prevention of viral hepatitis-related hepatocellular carcinoma
by: Athraa Falah Alshimerry, et al.
Published: (2023-01-01)

Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report
by: Jürgen Kurt Rockstroh, et al.
Published: (2010-07-01)

Regulation of the HBV Entry Receptor NTCP and its Potential in Hepatitis B Treatment
by: Yan Li, et al.
Published: (2022-04-01)

The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients
by: Chih-Wei Tseng, et al.
Published: (2022-08-01)

Hepatitis B Virus-Encoded MicroRNA (HBV-miR-3) Inhibits FIH-1 Expression to Promote Tumor Angiogenesis in HBV-Related Hepatocellular Carcinoma
by: Chen H, et al.
Published: (2023-12-01)